Efficacy and prognostic factors of anti-PD1 and nivolumab-ipilimumab therapy in advanced melanoma patients resistant to prior ICI treatment
Abstract Immune checkpoint inhibitors (ICIs) have significantly improved the five-year survival rate for advanced melanoma. However, many patients exhibit resistance to ICI therapy. This study evaluated the efficacy and prognostic factors of anti-PD-1 (Group A) and nivolumab–ipilimumab (Group B) the...
Sparad:
| Huvudupphov: | , , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Utgiven: |
Springer
2024-12-01
|
| Serie: | Discover Oncology |
| Ämnen: | |
| Länkar: | https://doi.org/10.1007/s12672-024-01702-w |
| Taggar: |
Inga taggar, Lägg till första taggen!
|